So, here’s a number that sounds utterly straightforward: 13. But in the high-stakes world of patent litigation, especially for pharmaceuticals, ‘pH of 13 or higher’ became a veritable Rorschach test for the Federal Circuit. The Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. case, a follow-up to a 2023 decision, drags this seemingly simple chemical measurement through the mud, proving that in law, even the most basic terms can require a Ph.D. in context.
What’s fascinating, and frankly, a bit infuriating if you’re looking for clarity, is that this isn’t the first time this precise patent claim has landed on the Federal Circuit’s doorstep. The initial go-round in 2023 punted the ball back to the district court, essentially saying, ‘Hold on, you need to look at stuff outside the patent document itself before you decide what ‘pH of 13’ actually means.’ Turns out, this phrase had two distinct layers of ambiguity, not just one. Fancy that.
The first appeal, bless their hearts, grappled with the number itself. Does ‘13’ mean 13.0? 13.00? How many decimal places are we talking about in the grand scheme of chemical formulation? Now, this latest skirmish, decided on May 13, 2026, tackles another wrinkle: temperature. Apparently, the pH of a solution isn’t a static, unchangeable number. It can shift depending on whether you’re measuring it at room temperature or when it’s bubbling away in the manufacturing vat. Who knew?
And this is where the whole thing gets really interesting, or at least, really telling about how patent law operates. The court had to resort to what they call ‘extrinsic evidence’ – basically, looking at dictionaries, scientific literature, expert testimony, anything but the patent’s own words and specifications – to nail down the meaning. This is a taxpayer-funded exercise in defining the obvious, yet again.
The Doctrine of Equivalents Takes a Hit
But wait, there’s more. Beyond the definitional gymnastics, Actelion also tried to argue their way around Mylan’s product using the doctrine of equivalents. This is the legal argument that says, ‘Okay, my patent might not exactly cover your product, but your product does essentially the same thing in essentially the same way to achieve the same result, so you’re still infringing.’ It’s often a lifeline for patent holders when competitors try to skirt the edges of a claim. Not so much this time.
The Federal Circuit knocked down Actelion’s doctrine of equivalents theory on two separate counts: prosecution history estoppel (meaning Actelion had argued something against patentability during the application process that now contradicted their infringement claim) and the disclosure-dedication rule (which essentially says if you disclose something in your patent application but don’t claim it, you’ve given up the right to claim it later). This makes it the second time in a week this particular legal lifeboat capsized for Actelion, following a similar ruling in the Bissell case.
So, what’s the takeaway here, besides the fact that patent law seems designed to create as much confusion as possible? It’s a stark reminder that patent claims, especially in technical fields, are rarely as clear-cut as they appear. A number on a page, a chemical measurement, can become a Rorschach test, requiring a deep dive into external context and potentially scuttling even strong infringement arguments. For those of us on the outside, it’s a proof to the endless quest for certainty in a system that often thrives on ambiguity.
And who’s making money here? Well, the lawyers certainly are. The patent attorneys, the patent agents, the judges, the expert witnesses – they’re all getting paid to sort through this mess. The pharmaceutical companies? They’re locked in a multi-year, multi-million-dollar battle over what a number means. The end-users, the patients? They’re likely just hoping their medication works, oblivious to the complex legal dance being performed in their name.
Why Does a Simple pH Matter So Much?
It’s easy to dismiss a dispute over ‘pH 13’ as academic pedantry. But in the pharmaceutical industry, precise chemical formulations are everything. A slight deviation can impact efficacy, stability, and most importantly, patent protection. When a patent claims a drug formulation based on a specific pH range, that range becomes a critical barrier to entry for competitors. If a generic drug maker can demonstrate their formulation falls outside that patented range, or if the patent holder can’t definitively prove infringement because the claimed range itself is ill-defined, it opens the door for competition. This case underscores that the patent office and courts must ensure claim language is precise enough to be objectively understood, or risk creating decades-long legal quagmires over what seem like trivial details to the uninitiated.
Is This a Win for Generic Drug Makers?
From one perspective, yes. The repeated need for extrinsic evidence and the Federal Circuit’s scrutiny on the doctrine of equivalents suggest that Actelion’s patent protection around this specific formulation might be weaker than they’d hoped. For Mylan and other potential generic competitors, this creates breathing room. The more ambiguities that need external clarification, the more opportunities there are to argue non-infringement or invalidity. However, this isn’t a clean sweep. The case is ongoing, and the ultimate construction of the claim, along with the resolution of other potential infringement arguments, will determine the true victor.
🧬 Related Insights
- Read more: Senators Demand AI Video Apps Halt IP Theft | ByteDance in Crosshairs
- Read more: IPR Petitions Plummet: Is the USPTO Killing Patent Challenges? [2026]
Frequently Asked Questions
What is the main takeaway from the Actelion v. Mylan pH 13 case?
The case demonstrates that seemingly simple claim terms in patents, like ‘pH 13’, can be highly ambiguous and require external evidence for interpretation, impacting infringement analysis and potentially weakening patent protection.
Why did the Federal Circuit need to look at ‘extrinsic evidence’?
Extrinsic evidence was necessary because the term ‘pH of 13 or higher’ in the patent claim was found to be ambiguous. This ambiguity related to both the precision of the number ‘13’ and how temperature affects the pH measurement, neither of which could be definitively resolved solely by reading the patent document itself.
How does this affect the doctrine of equivalents?
The case rejected Actelion’s doctrine of equivalents argument on two grounds (prosecution history estoppel and disclosure-dedication rule), indicating that competitors cannot easily argue infringement based on substantial similarity if the patent holder has previously made limiting statements or failed to claim related aspects.
